Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis ...Middle East

WALTHAM, Mass., Dec. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, provided an update regarding the appeal to...

Hence then, the article about ardelyx provides update on fda appeal for xphozah tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis was published today ( Saturday 17/12/2022 - 04:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis )

Also on site :

• Meet the ex-Google CMO who quit with a seven-figure package by 28—he says getting promoted was easy because he just ‘disregarded all the rules’
• REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
• Displaced families in Sudan struggle as aid falls short